Aiming to conduct more efficient clinical research?
We focus on transparency.

Associate member

The SCTO is an independent organisation and is based on a joint initiative of the Swiss National Science Foundation and the Swiss Academy of Medical Sciences.

As of 2017, the SCTO is a research infrastructure of national importance funded by the State Secretariat of Education, Research and Innovation and the Swiss National Science Foundation.

Symposium 2021

Event postponed to 2021

In the light of the current developments and the fact that the European Commission postponed the application of the Medical Devices Regulation by one year to prioritise the fight against coronavirus, we will hold our SCTO Symposium on 8 June 2021, instead of June 2020. The topic remains highly relevant and hence, we are adhering to the planned programme. 

European Commission postpones application of the Medical Devices Regulation to prioritise the fight against coronavirus

10th SCTO Symposium

Medical devices: lost in translation?

The SCTO is holding its annual symposium together with the Inselspital (Bern University Hospital), the University of Bern, and sitem-insel AG (Swiss Institute for Translational and Entrepreneurial Medicine). For the tenth time, we will explore the challenges and solutions that lie ahead in clinical research in an international context.

Local and international speakers will share their perspectives on medical devices (MDs) in clinical development and address the following important questions:

  • What are the specific challenges of MDs in translational medicine?
  • New laws and regulations for the clinical development of MDs: What is the current situation in Europe?
  • Where do we stand in Switzerland?
  • What training is needed and what is currently available?

Furthermore, researchers from Switzerland will share

  • an academic success story of MD translational development and
  • a case study of patient-driven MD development

And finally, an Oxford-style debate will reveal arguments for and against the statement: “Only (randomised) clinical trials generate sufficient evidence to finally put a MD (class III) on the market” (Or to what extent can real-world evidence replace them?)


Published in February 2020